FDA reviews Boehringer's Spiriva HandiHaler for stroke risk

The FDA announced Tuesday that it is conducting a safety review of Boehringer Ingelheim's Spiriva HandiHaler, a treatment for chronic obstructive pulmonary disease, after the company reported that it may increase the risk of stroke. The agency has asked the company to submit more data on the inhaler but warned patients against discontinuing treatment without proper medical advice.

View Full Article in:

Washington Post (tiered subscription model), The · Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC